Related references
Note: Only part of the references are listed.Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1
Teresa S. Hawley et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias
Robert O'Connor et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma
Francesca Gay et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2013)
Novel Generation of Agents With Proven Clinical Activity in Multiple Myeloma
Maria-Victoria Mateos et al.
SEMINARS IN ONCOLOGY (2013)
Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma
A. A. Chanan-Khan et al.
BLOOD CANCER JOURNAL (2013)
Drug interaction between lenalidomide and itraconazole
Naoto Takahashi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Targeting MDR in breast and lung cancer: Discriminating its potential importance from the failure of drug resistance reversal studies
Laleh Amiri-Kordestani et al.
DRUG RESISTANCE UPDATES (2012)
Genetic variations in multiple myeloma II: association with effect of treatment
Annette Vangsted et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2012)
Can we change the disease biology of multiple myeloma?
Ivan Borrello
LEUKEMIA RESEARCH (2012)
Overexpression of MDR1 and survivin, and decreased Bim expression mediate multidrug-resistance in multiple myeloma cells
Masanobu Tsubaki et al.
LEUKEMIA RESEARCH (2012)
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
Philip L. McCarthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Inactivating PSMB5 Mutations and P-Glycoprotein (Multidrug Resistance-Associated Protein/ATP-Binding Cassette B1) Mediate Resistance to Proteasome Inhibitors: Ex Vivo Efficacy of (Immuno)Proteasome Inhibitors in Mononuclear Blood Cells from Patients with Rheumatoid Arthritis
Sue Ellen Verbrugge et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
Yuan Xiao Zhu et al.
BLOOD (2011)
Phase I Trial of Lenalidomide and CCI-779 in Patients With Relapsed Multiple Myeloma: Evidence for Lenalidomide-CCI-779 Interaction via P-Glycoprotein
Craig C. Hofmeister et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Proteasome Regulator Marizomib (NPI-0052) Exhibits Prolonged Inhibition, Attenuated Efflux, and Greater Cytotoxicity than Its Reversible Analogs
Amanda Obaidat et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Doxorubicin induces drug efflux pumps in Candida albicans
Grzegorz Kofla et al.
MEDICAL MYCOLOGY (2011)
Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin
Gabriele Buda et al.
ANNALS OF HEMATOLOGY (2010)
Increased ABCB1 Expression in TP-110-Resistant RPMI-8226 Cells
Masatomi Iijima et al.
BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY (2010)
The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma
Paul A. Spagnuolo et al.
BLOOD (2010)
Comparative effects of drugs on P-glycoprotein expression and activity using rat and human trophoblast models
D. Beghin et al.
TOXICOLOGY IN VITRO (2010)
Influx and efflux transport as determinants of melphalan cytotoxicity: Resistance to melphalan in MDR1 overexpressing tumor cell lines
Annett Kuehne et al.
BIOCHEMICAL PHARMACOLOGY (2009)
Thalidomide alters nuclear architecture without ABCB1 gene modulation in drug-resistant myeloma cells
Aurelie Trussardi-Regnier et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2009)
Polymorphisms and haplotypes in the multidrug resistance 1 gene (MDR1/ABCB1) and risk of multiple myeloma
Krzysztof Jamroziak et al.
LEUKEMIA RESEARCH (2009)
Psorospermin structural requirements for P-glycoprotein resistance reversal
Steven S. Carey et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
Donna M. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors
Holger Rumpold et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes
Yasunori Nakagawa et al.
AMERICAN JOURNAL OF HEMATOLOGY (2006)
Multidrug reverting activity toward leukemia cells in a group of new verapamil analogues with low cardiovascular activity
M Biscardi et al.
LEUKEMIA RESEARCH (2006)
Insights into oxazaphosphorine resistance and possible approaches to its circumvention
J Zhang et al.
DRUG RESISTANCE UPDATES (2005)
Immunosuppressors and reversion of multidrug-resistance
N Aouali et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2005)
Major contribution of the multidrug transporter P-glycoprotein to reduced susceptibility of poly(ADP-ribose) polymerase-1 knock-out cells to doxorubicin action
J Wesierska-Gadek
JOURNAL OF CELLULAR BIOCHEMISTRY (2005)
Long-term thalidomide therapy resulted in lack of mdr1 gene expression in a patient with primary resistant multiple myeloma
M Hus et al.
LEUKEMIA (2005)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo
B Lin et al.
BLOOD (2005)
Functional imaging of multidrug resistant phenotype by 99mTc-MIBI scan in patients with multiple myeloma
R Fonti et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2004)
Cytotoxic effect in vivo and in vitro of CHS 828 on human myeloma cell lines
P Hovstadius et al.
ANTI-CANCER DRUGS (2004)
Overcoming drug resistance in multiple myeloma: The emergence of therapeutic approaches to induce apoptosis
HH Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer with P-glycoprotein expression
JJ Yeh et al.
RESPIRATION (2003)
Multidrug resistance in cancer: Role of ATP-dependent transporters
MM Gottesman et al.
NATURE REVIEWS CANCER (2002)
Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma
H Schwarzenbach
MEDICAL ONCOLOGY (2002)
Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: An EORTC-HOVON randomized phase III study (06914)
P Sonneveld et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study
AF List et al.
BLOOD (2001)
From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance
T Litman et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2001)
A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma
SV Rajkumar et al.
CANCER TREATMENT REVIEWS (2000)
Multidrug resistance (MDR) in cancer - Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs
R Krishna et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2000)
Share Paper
